Related Experiment Videos
Labetalol in the treatment of hypertensive renal patients
Insights
Labetalol effectively lowers blood pressure in patients with chronic renal failure and hypertension, serving as a good alternative to combined therapies. While not as potent as minoxidil, it shows significant benefits with few side effects.
Area of Science:
- Nephrology
- Cardiology
- Clinical Pharmacology
Background:
- Hypertension is a common comorbidity in patients with chronic renal failure.
- Managing blood pressure in this population is crucial for preventing further kidney damage and cardiovascular events.
- Existing antihypertensive regimens, including beta-blockers and hydralazine, may have limitations or side effects.
Purpose of the Study:
- To evaluate the efficacy of labetalol in lowering blood pressure in patients with chronic renal failure and hypertension.
- To assess labetalol as a substitute for prior antihypertensive therapies.
- To monitor changes in glomerular filtration rate and blood pressure parameters during labetalol treatment.
Main Methods:
- A study involving 18 patients with chronic renal failure and hypertension.
- Labetalol was substituted for existing antihypertensive therapy (beta-blocker and hydralazine) over four weeks.
- Glomerular filtration rate was measured using 51Cr edetic acid (EDTA) at baseline, one month, and six months.
Main Results:
- A significant reduction in supine systolic and erect systolic and diastolic blood pressure was observed.
- 12 out of 18 patients initially had diastolic blood pressure ≥ 100 mm Hg; this reduced to 4 out of 14 patients at six months.
- Transient postural dizziness was the most common side effect; pulse rate remained stable.
Conclusions:
- Labetalol is an effective antihypertensive agent for patients with chronic renal failure, offering a viable alternative to combined beta-blocker and hydralazine therapy.
- The drug demonstrates significant blood pressure-lowering effects, particularly in the erect position, with a favorable side effect profile.
- While effective, labetalol's potency may be less than that of minoxidil.
Abstract:
The efficacy of labetalol in lowering blood pressure was assessed in 18 patients with chronic renal failure and hypertension. Before the start of labetalol therapy, all patients were receiving combined antihypertensive therapy, the most common being a beta-blocker and hydrallazine. Over the period of about four weeks labetalol was substituted for the prior therapy. 51Cr edetic acid (EDTA) estimations of glomerular filtration rate were performed before labetalol therapy, and then again after one and six months. Before the therapy with labetalol, 12 of the 18 patients had supine diastolic blood pressures of 100 mm Hg or more. At six months, 14 patients remained in the trial and, of these, only four had a supine diastolic blood pressure of 100 mm Hg or more. In the supine position there was a significant reduction of systolic, but not of diastolic, blood pressure. However, in the erect position there was a significant reduction both in systolic and in diastolic blood presure. Pulse rate did not vary significantly. Few side effects were encountered, transient postural dizziness being the most common side effect. Labetalol seems to be an effective substitute for the beta-blocker plus hydrallazine therapy. However, it is not as potent as minoxidil.